190 related articles for article (PubMed ID: 34357770)
1. Impact of Target Turnover on the Translation of Drug-Target Residence Time to Time-Dependent Antibacterial Activity.
Basu R; Wang N; Basak S; Daryaee F; Babar M; Allen EK; Walker SG; Haley JD; Tonge PJ
ACS Infect Dis; 2021 Sep; 7(9):2755-2763. PubMed ID: 34357770
[TBL] [Abstract][Full Text] [Related]
2. Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors.
Basak S; Li Y; Tao S; Daryaee F; Merino J; Gu C; Delker SL; Phan JN; Edwards TE; Walker SG; Tonge PJ
J Med Chem; 2022 Sep; 65(17):11854-11875. PubMed ID: 36037447
[TBL] [Abstract][Full Text] [Related]
3. Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability.
Davoodi S; Daryaee F; Chang A; Walker SG; Tonge PJ
ACS Infect Dis; 2020 Apr; 6(4):629-636. PubMed ID: 32011855
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.
Lee CJ; Liang X; Gopalaswamy R; Najeeb J; Ark ED; Toone EJ; Zhou P
ACS Chem Biol; 2014 Jan; 9(1):237-46. PubMed ID: 24117400
[TBL] [Abstract][Full Text] [Related]
5. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
6. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
Erwin AL
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
[TBL] [Abstract][Full Text] [Related]
8. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
[TBL] [Abstract][Full Text] [Related]
12. Heterobivalent Inhibitors of Acetyl-CoA Carboxylase: Drug Target Residence Time and Time-Dependent Antibacterial Activity.
Cifone MT; He Y; Basu R; Wang N; Davoodi S; Spagnuolo LA; Si Y; Daryaee T; Stivala CE; Walker SG; Tonge PJ
J Med Chem; 2022 Dec; 65(24):16510-16525. PubMed ID: 36459397
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
Odenholt-Tornqvist I
Scand J Infect Dis Suppl; 1989; 58():1-55. PubMed ID: 2499924
[TBL] [Abstract][Full Text] [Related]
14. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
[TBL] [Abstract][Full Text] [Related]
15. Isolation and in-vitro and in-vivo characterisation of a mutant of Pseudomonas aeruginosa PAO1 that exhibited a reduced postantibiotic effect in response to imipenem.
Majcherczyk PA; Kunz S; Hattenberger M; Vaxelaire J; Zak O; O'Reilly T
J Antimicrob Chemother; 1994 Oct; 34(4):485-505. PubMed ID: 7646646
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
[TBL] [Abstract][Full Text] [Related]
17. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.
Langsdorf EF; Malikzay A; Lamarr WA; Daubaras D; Kravec C; Zhang R; Hart R; Monsma F; Black T; Ozbal CC; Miesel L; Lunn CA
J Biomol Screen; 2010 Jan; 15(1):52-61. PubMed ID: 20019290
[TBL] [Abstract][Full Text] [Related]
18. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
20. Post-antibacterial effect of thymol.
Zarrini G; Delgosha ZB; Moghaddam KM; Shahverdi AR
Pharm Biol; 2010 Jun; 48(6):633-6. PubMed ID: 20645735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
